Adipotide vs GHRP-6
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
- Half-Life
- Estimated 2-4 hours
- 15–60 minutes
- Admin Route
- Subcutaneous, Intravenous (research)
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- Not established for humans; primate studies used 0.1-1 mg/kg
- 100–300 mcg
- Frequency
- Daily for 4 weeks (research protocol)
- 2–3 times daily
- Key Benefits
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Strong GH stimulation
- Elevated IGF-1
- Muscle growth and recovery support
- Potential anti-inflammatory effects at GI level
- Useful for patients with appetite deficiency or cachexia
- Enhanced recovery from training
- Side Effects
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Intense hunger surge (30–45 min post-injection)
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —